Efficacy and Safety of Sirolimus to Vascular Anomalies

Inclusion Criteria

• •All patients included in the present research must be diagnosed with one of the following vascular anomalies:
• •1. Kaposiform Hemangioendotheliomas without Kasabach-Merritt Phenomenon
• •2. Tufted Angioma without Kasabach-Merritt Phenomenon
• •3. Capillary Malformations
• •4. Lymphatic Malformations
• •5. Venous Malformations
• •6. Capillary-Venous Malformation (CVM)
• •7. Capillary-Lymphatic Malformation (CLM)
• •8. Lymphatic-Venous Malformation (LVM)
• •9. Capillary-Lymphatic-Venous Malformation (CLVM)
• •10. Multifocal Lymphangiomatosis and Thrombocytopenia (MLT)
• •Patients must be 0 - 18 years of age at the time of study entry.
• •Without functional impairment requiring treatment of corticosteroid.
• •Organ function requirements:
• •Adequate liver function Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x upper limit normal (ULN) for age.
• •Adequate renal function 0-5 years of age maximum serum creatinine (mg/dL) of 0.8 6-10 years of age maximum serum creatinine (mg/dL) of 1.0 11-15 years of age maximum serum creatinine (mg/dL) of 1.2 16-18 years of age maximum serum creatinine (mg/dL) of 1.5
• •Adequate bone marrow function:
• •Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter
• •Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.